割抵抗性前列腺癌进展的分子机制
Abdulghani A Naeem1,2, Saud A Abdulsamad1,2
1Basic Sciences, College of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences, Jeddah, SAU.
Cureus
|June 10, 2025
概括
这项研究揭示了推动割抵抗性前列腺癌 (CRPC) 进展的关键分子变化. 已识别的基因和途径为诊断和治疗晚期前列腺癌提供了潜在的新目标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 前列腺癌是全球癌症死亡的主要原因之一.
- 了解转变为抵抗割的前列腺癌 (CRPC) 对于改善患者的治疗结果至关重要.
- 驱动CRPC进展的分子机制仍然不完全理解.
研究的目的:
- 调查前列腺癌发展为抵抗割的前列腺癌 (CRPC) 的分子机制.
- 识别差异表达基因 (DEG) 和参与CRPC发育的关键分子通路.
主要方法:
- 差异基因表达分析比较前列腺上皮细胞系 (PNT2) 与CRPC细胞系 (PC3M).
- 生物复制物的RNA测序以识别DEGs (折叠变化≥1,p<0.05).
- 功能性丰富分析 (基因本体学,KEGG途径) 和加权基因共同表达网络分析 (WGCNA).
主要成果:
- 在PNT2和PC3M细胞系之间确定了1000个差异表达的基因.
- 突出十大显著改变的基因和途径,包括代谢放松调节和细胞循环调节.
- WGCNA确定了重要的共同表达模块,并确定了关键路径中的关键DEG.
结论:
- 显著的分子变化,特别是代谢和细胞循环途径,与CRPC的发展有关.
- 已识别的DEG和途径为前列腺癌进展提供了新的见解.
- 这些发现表明CRPC的潜在诊断和治疗点,需要进一步的临床验证.
相关概念视频
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K


